Loading chat...

MD HB1109

Bill

Official Source

Status

Introduced

2/5/2025

Primary Sponsor

Jesse Pippy

Click for details

Origin

House of Delegates

2025 Regular Session

AI Summary

  • Retailers may only sell medetomidine or xylazine products to purchasers who provide proof of institutional, veterinary, or scientific intended use
  • Sales of medetomidine and xylazine products to individuals under age 21 are prohibited
  • Retailers must maintain records of all sales, including copies of purchaser identification and documentation of intended use
  • Civil penalties for violations are up to $3,000 for a first offense and $6,500 for each subsequent violation, with penalties deposited into the Maryland Substance Abuse Fund
  • Effective date: October 1, 2025

Legislative Description

Public Health - Medetomidine and Xylazine Consumer Protection Act

Records

Last Action

Hearing 3/05 at 2:40 p.m.

3/5/2025

Committee Referrals

Health and Government Operations2/5/2025

Full Bill Text

No bill text available